Amgen (AMGN) reported third-quarter adjusted earnings of $6.45 per share on Tuesday, beating estimates by 11% and lifting its full-year sales outlook to as much as $39.7 billion, underscoring a broadening product base that has driven shares up 41% in 2026.
For long-horizon investors, the results matter less as a single-quarter beat and more as evidence that Amgen’s revenue mix is shifting away from aging, biosimilar-exposed franchises toward higher-growth cardiovascular and bone-health products that carry longer runway.
Key Takeaways
- Q3 adjusted EPS of $6.45 topped the $5.79 consensus by 11%.
- Repatha cholesterol sales jumped 37% to $1.09 billion, beating estimates.
- Full-year sales guidance raised to $38.9-$39.7 billion at midpoint.
Market Reaction & Context
Amgen stock closed Tuesday in a technical buy zone after breaking out of a consolidation pattern, but retreated nearly 2% to roughly $452.53 in after-hours trading as investors digested the mixed product-level detail beneath the headline beat 1. Year-to-date, shares have climbed 41%, nearly double the 21% gain posted by IBD’s Medical-Profitable Biotech industry group, reflecting a Relative Strength Rating of 95 out of 99.
That sector outperformance is notable given broader pharmaceutical headwinds, including pricing pressure and biosimilar competition that has weighed on peers with more concentrated revenue bases.
Detailed Analysis: Winners and Laggards
Total third-quarter revenue rose 8% year over year to $10.37 billion, clearing the $10.07 billion Wall Street consensus, according to FactSet 1. The company said 17 products recorded double-digit sales growth during the period, pointing to breadth rather than reliance on a single blockbuster.
Repatha, the PCSK9 inhibitor for cholesterol management, was the clearest standout, generating $1.09 billion – up 37% and ahead of the $1.04 billion estimate. Evenity, the bone-building osteoporosis treatment, added $751 million, up 39% and above the $722 million consensus. Cancer drug Blincyto contributed $496 million, a 27% increase that edged past the $491 million forecast.
On the other side of the ledger, Prolia – which faces mounting biosimilar competition – slumped 45% to $632 million, well short of the $695 million estimate. Tepezza, acquired through the Horizon Therapeutics deal, fell 6% to $526 million versus the $585 million projection; management said lower inventory levels were the primary cause. Asthma treatment Tezspire posted a 43% volume-driven sales gain but still missed at $538 million against a $548 million consensus.
The divergence between growing franchises and biosimilar-pressured assets illustrates a revenue mix in active transition – a dynamic long-term investors will need to monitor as Prolia’s decline accelerates and pipeline products move to fill the gap.
Outlook & Guidance
Amgen raised its full-year 2026 sales guidance to a range of $38.9 billion to $39.7 billion, lifting the midpoint by approximately $500 million versus its prior forecast. It also raised its adjusted earnings per share outlook to $22.90-$23.70, up from $22.30-$23.50 previously, surpassing analyst consensus at the midpoint in both metrics 1.
“Amgen hikes 2026 guidance,” the company said in its earnings release, projecting adjusted EPS at the midpoint above analysts’ $23.06 estimate.
The guidance lift, combined with the breadth of double-digit product growth, suggests management has confidence that rising Repatha, Evenity, and Blincyto volumes can more than offset continued pressure on Prolia and Tepezza through year-end.
Pipeline Durability: The Longer View
For investors with a multi-year horizon, the Q3 results offer a rough blueprint of where Amgen’s revenue mix is heading: cardiovascular and autoimmune expansion driving incremental growth while legacy franchises face structural headwinds. Repatha’s trajectory into the $1 billion-plus quarterly range is particularly significant given the still-underpenetrated PCSK9 inhibitor market globally.
Biosimilar erosion of Prolia, once a cornerstone revenue driver, will likely remain a persistent drag through the near term, making the pace of Evenity and pipeline progression increasingly important to watch for margin sustainability. Comparisons to other sectors navigating cyclical revenue replacement – such as energy majors balancing legacy asset cash flows against new investments, as seen in Aramco’s recent earnings resilience – underscore that revenue mix transitions are a common long-cycle challenge across industries.
Conclusion
Amgen’s Q3 results confirm that the biotech’s current outperformance rests on a widening set of growth assets, most notably Repatha and Evenity, rather than a single catalyst. The 41% share-price gain in 2026 appears grounded in earnings delivery and rising guidance, though the persistent Prolia decline and Tepezza miss are reminders that the transition is incomplete.
Long-term investors should track the pace at which newer franchises replace biosimilar-exposed revenue, and monitor whether Amgen’s pipeline can sustain double-digit product growth beyond the current cycle.
Not investment advice. For informational purposes only.
References
1Gatlin, Allison (2026-11-03). “Amgen, Up 41% This Year, Is Broadly Outperforming Its Peers. Here’s What Its Earnings Say.” Investor’s Business Daily. Retrieved 2026-11-03.